ARV110 is a novel proteolytic targeting chimera (PROTAC), which binds to the androgen receptor at one end and cereblon E3 ligase at the other end, and is an orally active specific androgen receptor (AR) PROTAC degrader. It has clinical potential as an oral therapy for metastatic castration-resistant prostate cancer. Can be used for prostate cancer research.
ARV-110
| Cat# | Name | Structure | Pricing |
|---|---|---|---|
| AP14691 | ARV-110 | Pricing |
